Two different CAR-T assets in clinical stage through Partnerships:
- CD19 CAR-T therapy for Non Hodgkin’s Lymphoma (NHL)
- Bi-specific CAR targeting CD19 and CD22 in relapsed/refractory
Diffuse Large B Cell Lymphoma (DLBCL)
|PRODUCT||TARGET||INDICATION||RESEARCH||PRE-CLINICAL STAGE||CLINICAL STAGE|
|MTB–001||CD19||Non Hodgkin’s Lymphoma (NHL)|
|MTB-002||CD19 and CD22||relapsed/refractory (r/r) Diffuse Large B Cell Lymphoma (DLBCL):|
MTB-001: IND approved; US trials through our partner; global trials through MedTherapy
MTB-002: Similar constructs under Phase-I. MedTherapy Phase I starting in 2023
MTB-003, MTB-004, MTB-005: Co-development with our partners.
Next-generation CAR-T cell therapies
- Ability to rapidly and cost-effectively manufacture and scale up CD19 CAR-T cells
- Development of novel CD19 CAR technology that demonstrates similar or improved efficacy to other clinically used CD19 CAR products
- Our CAR-T cells demonstrate similar or improved in vitro and in vivo efficacy to commercial CAR-T products against human lymphoma cells
- Novel CAR design based on unique hinge and transmembrane domains with high level of CAR expression and activity (IP filed by our collaborating partner)
- Our CAR-T cells maintain immature/memory phenotype and demonstrate enhanced circulating CAR-T cells
- Delivery Time = 1 week; compared to 4-6 weeks for other commercial manufacturing
Next-generation technologies for CAR-T cell therapies
Innovative Manufacturing Technology:
Manufacturing CAR-T cell gene therapies is very complex. And time consuming – almost 4-6 weeks for a patient.
This leads to both- delays in manufacturing, and, exorbitant costs. MedTherapy has developed innovative technologies to speed up the process. Our technology allows to manufacture the therapy in a few days – instead of weeks!
Virus vector technology:
Our in-house global scale manufacturing facilities are capable for industry scale manufacturing for ourselves and our partners and collaborators.
Current, classical: quadruple transfection of adherent 293T cells in cell factories
Novel: quadruple transfection of 293T cells in suspension in bioreactors
Unique: lentiviral vectors produced from stable cell line (no plasmid DNA needed)
Disruptive: production of injectable targeted lentiviral vectors